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Rationale
Prostate cancer is one of the most common cancer found
in man. For patients with hormone-refractory, metastatic
tumour no effective therapy is available and prognosis is
very poor. Therefore we designed a clinical study using a
novel approach for the treatment of patients with
advanced stages of prostate cancer. Preliminary data con-
cerning dendritic cell (DC) based vaccination revealed
promising results but the clinical relevance is still ques-
tioned. Thus, we decided to develop a clinical protocol for
the treatment of 12 patients with hormone-refractory
prostate carcinoma using prostate-specific antigen (PSA)-
derived peptides loaded on DC.
Methods
PBMC from HLA-A2 positive patients are isolated from
the peripheral blood by Leucapheresis. Monocytes are
seperated by adherence and differentiated into immature
DC by incubation with GM-CSF and IL-4 under serumfree
conditions over six days. Then DC are matured with TNF-
α and PGE2 and pulsed with three different PSA-Peptides
(PSA-1 [FLTPKKLQCV]; PSA-2 [KLQCVDLHV]; PSA-3
[VISNDVCAQV]). For vaccination 6 × 106 Peptide-pulsed
DC are applied intracutaneously after previous subcutane-
ous application of INF-γ (50 µg/m2). Vaccination is per-
formed 4 times in 3 week intervals. Patients are included
after informed consent and sufficient hematological liver
and renal function. Primary end point of the trial is the
evaluation of PSA, measurable tumour parameter after 4
vaccinations and clinical benefit. Secondary end points
are safety, quality of life (EORTC-QLQ-C30) and immu-
nological parameters.
Results
Until now 8 patients are enrolled. 4 patients completed all
4 scheduled vaccination. 3 patients are still under vaccina-
tion. One patient dropped out due to early progress. The
vaccination is well tolerated without any therapy related
adverse event. Response rates are under evaluation and
will be presented.
Conclusion
Vaccination with PSA-peptide-pulsed autologous DC
combined with INF-γ is feasible and well tolerated. Fur-
ther evaluation is in progress.
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